Evidence map›Paper›PMID 40487594›Full record

ReviewIBRO neuroscience reports2025

Bridging neuro-biomarkers and MR imaging: The synergistic role of glial fibrillary acidic protein in early CNS disease diagnosis.

Mohammad Ghaderian, Daryoush Shahbazi-Gahrouei, Safoora Nikzad, Elnaz Didehban, Hossein Hafezi, Ismail Laher, Fahime Hossein Beigi, Saghar Shahbazi-Gahrouei, Tahereh Boustani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in IBRO neuroscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammad GhaderianDepartment of Radiopharmacy and Preclinical Imaging, University Hospital Tuebingen, Tuebingen, Germany.
Daryoush Shahbazi-GahroueiDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Iran.
Safoora NikzadDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Iran.
Elnaz DidehbanDepartment of Radiology, Namzai Hospital, Shiraz, Iran.
Hossein HafeziDepartment of Dermatology, Wake Forest School of Medicine, Winston Salem, NC, USA.
Ismail LaherDepartment of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, The University of British Colombia, Vancouver, Canada.
Fahime Hossein BeigiDepartment of Biophysics Falavarjan Branch, Islamic Azad University, Isfahan, Iran.
Saghar Shahbazi-GahroueiDepartment of Medical Physics, School of Medicine, Isfahan University of Medical Sciences, Iran.
Tahereh BoustaniDepartment of Medical Imaging, Namazi Hosptial, Shiraz, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular neuroimaging is a powerful and emerging tool for the early detection and monitoring of central nervous system (CNS)-related and neurodegenerative diseases. Biomarkers play a crucial role in diagnostic accuracy, prognosis, and treatment efficacy. Among these, Glial Fibrillary Acidic Protein (GFAP), a cytoskeletal intermediate filament protein, serves as a key indicator of astrocytic activation and neuroaxonal injury. Elevated levels of GFAP in cerebrospinal fluid (CSF) and blood-based samples (serum/plasma) are increasingly recognized as potential biomarkers for neurodegeneration and CNS pathology. Advanced molecular imaging techniques, including Diffusion Tensor Imaging (DTI) and Diffusion-Weighted Imaging (DWI), along with conventional magnetic resonance imaging (MRI), provide visual scoring, local morphometry, and volumetric analysis. Therefore, integrating GFAP with neuroimaging modalities offers the potential to improve disease characterization, allowing for accurate spatial mapping of neurodegeneration and monitoring of disease progression at a molecular level. The relationship between MRI and GFAP is currently under evaluation. This review explores the interplay between GFAP and molecular neuroimaging, highlighting their combined potential to enhance early diagnosis, prognosis, and treatment monitoring of CNS disorders.

Indexed as

CNS-related diseasesGlial fibrillary acidic proteinMagnetic resonance imagingNeurodegenerative diseases

Identifiers

PMID40487594
PMCPMC12141570

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.